Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination

Eric Sellem, Jean François Rouland, Christophe Baudouin, Alain Bron, Philippe Denis, Jean-Philippe Nordmann, Jean Paul Renard, Eric Sellem, Jean François Rouland, Christophe Baudouin, Alain Bron, Philippe Denis, Jean-Philippe Nordmann, Jean Paul Renard

Abstract

Background: Given the growing number of ocular hypotensive medications available, it is important to be able to predict a positive response to therapy. The purpose of the present study was to identify predictors of an additional 10% intraocular pressure (IOP) reduction after 12 weeks of treatment with latanoprost/timolol fixed combination (FC) in patients requiring a change in their previous ocular hypotensive medication.

Methods: This multicenter, open-label, prospective, phase IIIb study included subjects >or=18 years of age with open-angle glaucoma (OAG) or ocular hypertension (OHT). Eligible subjects had baseline IOP >or=21 mmHg and insufficient response to current beta-blocker monotherapy. The primary efficacy analysis (logistic regression) identified predictors of a positive response after 12 weeks of latanoprost/timolol FC.

Results: The intent-to-treat (ITT) population included 383 subjects treated with >or=1 drop of FC and having >or=1 follow-up IOP assessment. Mean IOP was 22.19 +/- 2.16 mmHg at baseline and was reduced by 5.42 +/- 2.71 mmHg at study end. In all, 325 (84.9%) subjects had a positive response to latanoprost/timolol FC; the response rate was similar across groups: OAG (n = 208; 82.7%); OHT (n = 161; 87.6%); OAG+OHT (n = 14; 85.7%). Higher baseline IOP (odds ratio: 1.284; 95% confidence interval [CI]: 1.101, 1.497; p = 0.0014) and absence of adverse events (odds ratio: 0.318; 95% CI: 0.161, 0.629; p = 0.0010) were significant predictors of positive response. Age, gender, ethnic origin, diagnosis, family history of OAG/OHT, corneal thickness, and concomitant systemic beta-blocker were not significant predictors of a positive response in the ITT analysis. The FC was well tolerated. The most common adverse events were related to the eye and were consistent with known adverse events associated with latanoprost and timolol.

Conclusions: These results support the use of latanoprost/timolol FC in patients whose IOP is insufficiently controlled on beta-blocker monotherapy. Patients with higher baseline IOP levels and who do not experience adverse events while on therapy are most likely to achieve a positive response to latanoprost/timolol FC.

Trial registration: ClinicalTrials.gov NCT00230763.

Figures

Figure 1
Figure 1
Subject disposition. FC = fixed combination.

References

    1. AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–440. doi: 10.1016/S0002-9394(00)00538-9.
    1. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505. doi: 10.1016/S0002-9394(98)00272-4.
    1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279.
    1. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48–56.
    1. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713.
    1. European Glaucoma Society Terminology and Guidelines for Glaucoma, IInd ed. Savona, Italy: DOGMA; 2008.
    1. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26:233–236.
    1. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA. 2002;288:2880–2883. doi: 10.1001/jama.288.22.2880.
    1. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care. 1998;36:1138–1161. doi: 10.1097/00005650-199808000-00004.
    1. Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431–436. doi: 10.1016/j.ophtha.2005.10.034.
    1. Xalacom®. Summary of Product Characteristics. November 2007. Electronic Medicines Compendium. Accessed: November 16, 2009.
    1. Diestelhorst M, Larsson LI. European Latanoprost Fixed Combination Study Group. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2004;88:199–203. doi: 10.1136/bjo.2003.018234.
    1. Diestelhorst M, Larsson LI. European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113:70–76. doi: 10.1016/j.ophtha.2005.06.027.
    1. Higginbotham EJ, Diestelhorst M, Pfeiffer N, Rouland JF, Alm A. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Surv Ophthalmol. 2002;47(Suppl 1):S133–S140. doi: 10.1016/S0039-6257(02)00295-3.
    1. Higginbotham EJ, Feldman R, Stiles M, Dubiner H. Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002;120:915–922.
    1. Pfeiffer N. European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002;240:893–899. doi: 10.1007/s00417-002-0553-0.
    1. Shin DH, Feldman RM, Sheu WP. Fixed Combination Latanoprost/Timolol Study Group. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology. 2004;111:276–282. doi: 10.1016/j.ophtha.2003.05.019.
    1. Lee BL, Gutierrez P, Gordon M, Wilson MR, Cioffi GA, Ritch R, Sherwood M, Mangione CM. The Glaucoma Symptom Scale. A brief index of glaucoma-specific symptoms. Arch Ophthalmol. 1998;116:861–866.
    1. Baudouin C, Rouland JF, Nordmann JP, Bron A, Pelen F. [Efficacy of first- or second-line latanoprost on intraocular pressure and ocular symptoms in patients with open-angle glaucoma or ocular hypertension] J Fr Ophtalmol. 2006;29:615–624. doi: 10.1016/S0181-5512(06)73821-9.
    1. Ringsdorf L, McGwin G Jr, Owsley C. Visual field defects and vision-specific health-related quality of life in African Americans and whites with glaucoma. J Glaucoma. 2006;15:414–418. doi: 10.1097/01.ijg.0000212252.72207.c2.
    1. Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19:572–579.
    1. Rulo AH, Greve EL, Geijssen HC, Hoyng PF. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology. 1996;103:1276–1282.
    1. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;10:95–104.
    1. Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 2002;47(Suppl 1):S77–S89. doi: 10.1016/S0039-6257(02)00310-7.
    1. Ang A, Reddy MA, Shepstone L, Broadway DC. Long term effect of latanoprost on intraocular pressure in normal tension glaucoma. Br J Ophthalmol. 2004;88:630–634. doi: 10.1136/bjo.2003.020826.
    1. Dawson-Saunders B, Trapp RB. Basic and Clinical Biostatistics. Norwalk, CT: Appleton & Lange; 1990.
    1. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393–398. doi: 10.1097/00061198-200310000-00001.
    1. Zimmerman TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther. 2009;25:145–152. doi: 10.1089/jop.2008.0072.
    1. AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol. 2002;134:499–512. doi: 10.1016/S0002-9394(02)01659-8.
    1. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP. CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943–1953. doi: 10.1016/S0161-6420(01)00873-9.
    1. Friedman DS, Wilson MR, Liebmann JM, Fechtner RD, Weinreb RN. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol. 2004;138(3 Suppl):S19–S31.
    1. Hamacher T, Schinzel M, Schölzel-Klatt A, Neff HM, Maier H, Schlaffer G, Beausencourt E, Jütte M, Scholz R, Lorger C, Stewart WC. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol. 2004;88:1295–1298. doi: 10.1136/bjo.2004.043232.
    1. Dunker S, Schmucker A, Maier H. Latanoprost/Timolol Fixed Combination Study Group. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther. 2007;24:376–386. doi: 10.1007/BF02849907.
    1. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomized, controlled trial. BMC Med Res Methodol. 2007;7:30. doi: 10.1186/1471-2288-7-30.
    1. Franke RH, Kaul JD. The Hawthorne experiments: First statistical interpretation. Am Sociol Rev. 1978;43:623–643. doi: 10.2307/2094540.
    1. Casson RJ, Liu L, Graham SL, Morgan WH, Grigg JR, Galanopoulos A, Crawford A, House PH. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study. J Glaucoma. 2009;18:582–588. doi: 10.1097/IJG.0b013e318199722b.
    1. Hatanaka M, Reis A, Sano ME, Susanna R. , JrAdditive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial. J Glaucoma. 2009. in press .
    1. Novack GD, David R, Lee PF, Freeman MI, Duzman E, Batoosingh AL. Effect of changing medication regimens in glaucoma patients. Ophthalmologica. 1988;196:23–28.
    1. Olander K, Zimmerman TJ, Downes N, Schoenfelder J. Xalacom/Latanoprost Study Group. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension. Clin Ther. 2004;26:1619–1629. doi: 10.1016/j.clinthera.2004.10.009.
    1. Pillunat LE, Larsson LI. European and Canadian Latanoprost Study Group. Intraocular pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open angle glaucoma. Br J Ophthalmol. 2003;87:1492–1496. doi: 10.1136/bjo.87.12.1492.
    1. Rhee DJ, Peace JH, Mallick S, Landry TA, Bergamini MV. the Study Group. A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2008;2:313–319.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel